Concepedia

Matthew S. Davids

MS

156

Publications

12.6K

Citations

52

H-Index

2001

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

The University of Texas MD Anderson Cancer Center

AbbVie (United States)

University of California San Diego

Matthew S. Davids is an author at Dana-Farber Cancer Institute specializing in medicine, immunology, and oncology.

Top concepts

MedicineImmunologyOncologyPathologyHematologyCancer ResearchImmunotherapyPharmacotherapyHealthRadiation Oncology

Publications per year

2001–2024

156

Publications

156

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel et al. · New England Journal of Medicine · 2015 · 1.8K citations · Full text

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Matthew S. Davids, Andrew W. Roberts, John F. Seymour et al. · Journal of Clinical Oncology · 2017 · 737 citations · Full text

Immunology, Pathology, Pharmacotherapy +17

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Matthew S. Davids, Haesook T. Kim, Pavan Bachireddy et al. · New England Journal of Medicine · 2016 · 588 citations · Full text

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study

Anthony R. Mato, Nirav N. Shah, Wojciech Jurczak et al. · The Lancet · 2021 · 432 citations · Full text

Phase 1/2, Lymphoid Neoplasia, Medicine +6

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial

Jeffrey A. Jones, Anthony R. Mato, William G. Wierda et al. · The Lancet Oncology · 2017 · 372 citations · Full text

Hematological Malignancy, Interim Analysis, Lymphoid Neoplasia +9

Rows per page

1–5 of 156